A Randomized, Open-Label Phase III Trial of BMS-936558 versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
What is the purpose of this trial?
Primary Objective: To compare the objective response rate (ORR) and overall survival (OS) of BMS-936558 to investigator's choice in subjects with advanced melanoma whose tumors are PD-L1 positive (PD-L1+population).
- 18 Years and older
- Bristol-Myers Squibb Company
- Last Updated:
- Study HIC#: